Ian McGowan, M.D., Ph.D., FRCP, is a professor of medicine in the division of gastroenterology, hepatology and nutrition with a joint appointment in the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine. In addition, Dr. McGowan is co-principal investigator of the University of Pittsburgh-based Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established in 2006 by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH).
Until joining the faculty of the University of Pittsburgh in September of 2007, Dr. McGowan was a professor of medicine and co-director of the Center for Prevention Research at the Dave Geffen School of Medicine, University of California Los Angeles, his academic home of five years.
A recognized authority on the development of microbicides, Dr. McGowan is principal investigator of three NIH-funded research programs, two of which are focused on the clinical development of rectal microbicides to prevent sexual transmission of HIV. One of these is a $3.8 million “U-19” Research Program Project called the Microbicide Development Program, which is undertaking the preclinical and early Phase I development of antiretroviral rectal microbicides. In the third NIH-funded program, Dr. McGowan is collaborating with the University of Oxford to develop aptamers as candidate microbicides for the prevention of HIV, HSV, and HPV infection. Aptamers are sequences of nucleic acid that bind and neutralize viral targets.
As co-principal investigator of the MTN, Dr. McGowan is intimately involved in the oversight and leadership of a major global effort that will design and implement an expansive portfolio of clinical trials of candidate microbicides at 20 clinical research sites in seven countries between 2006 and 2013. With its goal of reducing the sexual transmission of HIV through the development and evaluation of microbicides, the MTN is structured specifically to facilitate research required to support licensure of microbicide products for widespread use.
Dr. McGowan’s extensive industry experience and knowledge of domestic and international project management and regulatory aspects of drug development are brought to bear in MTN’s ambitious endeavors. Between 1997 and 2002, Dr. McGowan held a number of senior positions in the pharmaceutical industry, including as a director of clinical research at Gilead Sciences, where he was responsible for the Phase II/III clinical development of the antiretroviral drug tenofovir disoproxil fumarate (Viread®).
A native of England, Dr. McGowan obtained his medical degree from the University of Liverpool in the United Kingdom, where he also completed postgraduate training in internal medicine, infectious diseases and gastroenterology. Between 1989 and 1994, he was a fellow in sexually transmitted diseases and HIV medicine at Middlesex Hospital in London, during which time he obtained a doctoral degree in mucosal immunology from Oxford University. In 1994, Dr. McGowan left the U.K. for a post-doctoral fellowship in digestive diseases at UCLA.
Dr. McGowan is a member of the Royal College of Physicians, the Royal Society of Medicine, the American Gastroenterology Association, and the Society for Mucosal Immunology. He is a reviewer for several high-profile scientific and medical journals, including Science, AIDS, Gastroenterology and PLoS Medicine.
Dr. McGowan has served as a consultant for the U.S. Centers for Disease Control and Prevention, the World Health Organization, and currently sits on the U.S. Food and Drug Administration Antiviral Advisory Committee.
Ian McGowan, M.D., Ph.D., FRCP, is a professor of medicine in the division of gastroenterology, hepatology and nutrition with a joint appointment in the department of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh School of Medicine. In addition, Dr. McGowan is co-principal investigator of the University of Pittsburgh-based Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established in 2006 by the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH).
Until joining the faculty of the University of Pittsburgh in September of 2007, Dr. McGowan was a professor of medicine and co-director of the Center for Prevention Research at the Dave Geffen School of Medicine, University of California Los Angeles, his academic home of five years.
A recognized authority on the development of microbicides, Dr. McGowan is principal investigator of three NIH-funded research programs, two of which are focused on the clinical development of rectal microbicides to prevent sexual transmission of HIV. One of these is a $3.8 million “U-19” Research Program Project called the Microbicide Development Program, which is undertaking the preclinical and early Phase I development of antiretroviral rectal microbicides. In the third NIH-funded program, Dr. McGowan is collaborating with the University of Oxford to develop aptamers as candidate microbicides for the prevention of HIV, HSV, and HPV infection. Aptamers are sequences of nucleic acid that bind and neutralize viral targets.
As co-principal investigator of the MTN, Dr. McGowan is intimately involved in the oversight and leadership of a major global effort that will design and implement an expansive portfolio of clinical trials of candidate microbicides at 20 clinical research sites in seven countries between 2006 and 2013. With its goal of reducing the sexual transmission of HIV through the development and evaluation of microbicides, the MTN is structured specifically to facilitate research required to support licensure of microbicide products for widespread use.
Dr. McGowan’s extensive industry experience and knowledge of domestic and international project management and regulatory aspects of drug development are brought to bear in MTN’s ambitious endeavors. Between 1997 and 2002, Dr. McGowan held a number of senior positions in the pharmaceutical industry, including as a director of clinical research at Gilead Sciences, where he was responsible for the Phase II/III clinical development of the antiretroviral drug tenofovir disoproxil fumarate (Viread®).
A native of England, Dr. McGowan obtained his medical degree from the University of Liverpool in the United Kingdom, where he also completed postgraduate training in internal medicine, infectious diseases and gastroenterology. Between 1989 and 1994, he was a fellow in sexually transmitted diseases and HIV medicine at Middlesex Hospital in London, during which time he obtained a doctoral degree in mucosal immunology from Oxford University. In 1994, Dr. McGowan left the U.K. for a post-doctoral fellowship in digestive diseases at UCLA.
Dr. McGowan is a member of the Royal College of Physicians, the Royal Society of Medicine, the American Gastroenterology Association, and the Society for Mucosal Immunology. He is a reviewer for several high-profile scientific and medical journals, including Science, AIDS, Gastroenterology and PLoS Medicine.
Dr. McGowan has served as a consultant for the U.S. Centers for Disease Control and Prevention, the World Health Organization, and currently sits on the U.S. Food and Drug Administration Antiviral Advisory Committee.